Benjamin Koethe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Benjamin Koethe has a total of 139 co-authors. Here are the top co-authors by number of shared publications:
- Ayan R. Patel
CardioVascular Center, Tufts Medical Center , Boston, MA
3 shared publications - Ethan J. Rowin
Lahey Hospital and Medical Center
3 shared publications - Martin S. Maron
Lahey Hospital and Medical Center
3 shared publications Barry J. Maron
Hypertrophic Cardiomyopathy Institute, Division of Cardiology, Tufts Medical Center, Boston, Massachusetts
2 shared publications- Barry J. Maron
HCM Center, Lahey Hospital and Medical Center, Burlington, MA
2 shared publications - Benjamin S. Wessler
Tufts Clinical and Translational Science Institute, Tufts Medical Center, Tufts University , Boston, MA
2 shared publications
Latest Publications
- Open Access
- 6 October 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Imaging Methods and Practice
- Vol. 4 (4)
Assessment of cardiac image quality from single-probe handheld ultrasound devices
Aims: This study aims to assess quality of cardiac ultrasound imaging from commercially available single-probe handheld devices. Methods and results: Cardiac imaging from single-probe handheld ultrasound devices was prospectively acquired by registered cardiac sonographers. Videos were graded on a scale of 1 (uninterpretable) to 5 (diagnostic-quality imaging) by 2 sonographers. The average image quality score for each cine loop was analysed. Interpretable imaging was defined as an average IQ score ≥ 2. Good image quality was defined as an average IQ score ≥ 4. Imaging from single-probe devices representing 518 videos from 206 patients was assessed. The mean age was 72 (SD 11.1) years. Agreement on image quality was moderate (weighted kappa 0.50, 95% CI 0.45–0.55). The correlation between sonographer quality grades was 0.60. The median average IQ score was 2.5 (1.5). 454 (88%) of the videos were interpretable (average IQ ≥ 2). At least one interpretable video was obtained for 187 (91%) patients. 62/518 (12%) of videos had good image quality (average score ≥ 4). There was a trend towards lower image quality with increasing BMI categories [16–25, median 3.0 (2.0, 3.5), 25–29, median 3.0 (2.0, 3.5), > 29 median 2.5 (2.0, 3.0), P < 0.001]. Conclusion: Basic interpretable imaging from single-probe handheld ultrasound devices can be obtained for most patients under idealized conditions, suggesting possible use for enhanced cardiac disease detection. Since imaging from a significant minority of patients is uninterpretable and lower image quality is associated with higher BMI, rigorous assessment of image quality is essential prior to image interpretation.
- 6 October 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Imaging Methods and Practice
- Vol. 4 (4)
Open AccessAssessment of cardiac image quality from single-probe handheld ultrasound devices
Aims: This study aims to assess quality of cardiac ultrasound imaging from commercially available single-probe handheld devices. Methods and results: Cardiac imaging from single-probe handheld ultrasound devices was prospectively acquired by registered cardiac sonographers. Videos were graded on a scale of 1 (uninterpretable) to 5 (diagnostic-quality imaging) by 2 sonographers. The average image quality score for each cine loop was analysed. Interpretable imaging was defined as an average IQ score ≥ 2. Good image quality was defined as an average IQ score ≥ 4. Imaging from single-probe devices representing 518 videos from 206 patients was assessed. The mean age was 72 (SD 11.1) years. Agreement on image quality was moderate (weighted kappa 0.50, 95% CI 0.45–0.55). The correlation between sonographer quality grades was 0.60. The median average IQ score was 2.5 (1.5). 454 (88%) of the videos were interpretable (average IQ ≥ 2). At least one interpretable video was obtained for 187 (91%) patients. 62/518 (12%) of videos had good image quality (average score ≥ 4). There was a trend towards lower image quality with increasing BMI categories [16–25, median 3.0 (2.0, 3.5), 25–29, median 3.0 (2.0, 3.5), > 29 median 2.5 (2.0, 3.0), P < 0.001]. Conclusion: Basic interpretable imaging from single-probe handheld ultrasound devices can be obtained for most patients under idealized conditions, suggesting possible use for enhanced cardiac disease detection. Since imaging from a significant minority of patients is uninterpretable and lower image quality is associated with higher BMI, rigorous assessment of image quality is essential prior to image interpretation.
- 6 October 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (14) , 1290-1305
International Experience With Implantable Cardioverter Defibrillators for the Prevention of Sudden Death in High-Risk Patients With Hypertrophic Cardiomyopathy
BACKGROUND: Implanted cardioverter-defibrillators (ICDs) have been used in patients with hypertrophic cardiomyopathy (HCM) to prevent sudden death, and have proven lifesaving for many patients. However, experience with ICD therapy has largely been derived from relatively small HCM cohorts confined to specific countries or regions of the world. Therefore, we sought to determine the effectiveness of ICDs in preventing sudden death due to life-threatening ventricular arrhythmias in a large international multicenter HCM population. METHODS: Databases from 25 HCM centers (8 in the United States, 9 in Europe, 4 in Asia, and 1 each in Australia, Africa, Mexico, and South America) were retrospectively interrogated to identify consecutive patients with HCM with ICDs (1992 to 2024) followed for 7±6 years (up to 32 years) for clinical outcomes. RESULTS: A total of 3387 patients were identified (63% men). They had a mean left ventricular thickness of 22±7 mm. The participants had received ICDs at a mean age of 47±17 years. Over follow-up, 550 patients (16%) experienced ≥1 appropriate ICD therapy (2.6%/y), including 86 of the 247 implanted for secondary prevention (35% [6.4%/y]) and 464 of the 3140 implanted for primary prevention (15% [2.2%/y]). Appropriate therapy occurred in the 464 primary prevention patients at a mean age of 49±17 years, with a median time to first appropriate therapy of 4 years after ICD implantation; 16% of these received their first appropriate therapy ≥10 years after implantation, and 47% experienced multiple interventions. Independent predictors of appropriate ICD therapy included unexplained syncope, left ventricular apical aneurysms, left ventricular systolic dysfunction, and nonsustained ventricular tachycardia on ambulatory monitoring. Of the 3140 primary prevention patients, 2946 survived (94%) and 194 died (6%) (0.8%/y), including 68 due to HCM (0.3%/y), predominantly of end-stage heart failure (n=43) or stroke (n=9). In contrast, 11 patients (0.4%) died suddenly, with device failures occurring in 2.4% of those with life-threatening ventricular tachyarrhythmias. Survival free from HCM-related mortality at 10 and 20 years was 97% and 91%, respectively. CONCLUSIONS: In this international multicenter study, the largest to date, including >3300 consecutive patients with HCM and ICDs, device therapy terminated potentially lethal ventricular tachyarrhythmias in 1 of 6 patients, with low HCM-related mortality rates for patients with ICDs. These novel data demonstrate the effectiveness of the ICD initiative, which has probably favorably altered the natural history of many patients with HCM worldwide.
- 6 October 2026
- Published by Wolters Kluwer Health in Circulation
- Vol. 154 (14) , 1290-1305
International Experience With Implantable Cardioverter Defibrillators for the Prevention of Sudden Death in High-Risk Patients With Hypertrophic Cardiomyopathy
BACKGROUND: Implanted cardioverter-defibrillators (ICDs) have been used in patients with hypertrophic cardiomyopathy (HCM) to prevent sudden death, and have proven lifesaving for many patients. However, experience with ICD therapy has largely been derived from relatively small HCM cohorts confined to specific countries or regions of the world. Therefore, we sought to determine the effectiveness of ICDs in preventing sudden death due to life-threatening ventricular arrhythmias in a large international multicenter HCM population. METHODS: Databases from 25 HCM centers (8 in the United States, 9 in Europe, 4 in Asia, and 1 each in Australia, Africa, Mexico, and South America) were retrospectively interrogated to identify consecutive patients with HCM with ICDs (1992 to 2024) followed for 7±6 years (up to 32 years) for clinical outcomes. RESULTS: A total of 3387 patients were identified (63% men). They had a mean left ventricular thickness of 22±7 mm. The participants had received ICDs at a mean age of 47±17 years. Over follow-up, 550 patients (16%) experienced ≥1 appropriate ICD therapy (2.6%/y), including 86 of the 247 implanted for secondary prevention (35% [6.4%/y]) and 464 of the 3140 implanted for primary prevention (15% [2.2%/y]). Appropriate therapy occurred in the 464 primary prevention patients at a mean age of 49±17 years, with a median time to first appropriate therapy of 4 years after ICD implantation; 16% of these received their first appropriate therapy ≥10 years after implantation, and 47% experienced multiple interventions. Independent predictors of appropriate ICD therapy included unexplained syncope, left ventricular apical aneurysms, left ventricular systolic dysfunction, and nonsustained ventricular tachycardia on ambulatory monitoring. Of the 3140 primary prevention patients, 2946 survived (94%) and 194 died (6%) (0.8%/y), including 68 due to HCM (0.3%/y), predominantly of end-stage heart failure (n=43) or stroke (n=9). In contrast, 11 patients (0.4%) died suddenly, with device failures occurring in 2.4% of those with life-threatening ventricular tachyarrhythmias. Survival free from HCM-related mortality at 10 and 20 years was 97% and 91%, respectively. CONCLUSIONS: In this international multicenter study, the largest to date, including >3300 consecutive patients with HCM and ICDs, device therapy terminated potentially lethal ventricular tachyarrhythmias in 1 of 6 patients, with low HCM-related mortality rates for patients with ICDs. These novel data demonstrate the effectiveness of the ICD initiative, which has probably favorably altered the natural history of many patients with HCM worldwide.
- Open Access
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Effect of protein and alkali supplementation on bone turnover markers in healthy older adults
Purpose: To investigate the effects of whey protein (WP; 1.5 g/kg/day) and potassium bicarbonate (KHCO3; 81 mmol/day) supplementation on bone turnover markers in healthy older adults.Methods: We conducted a secondary analysis of healthy adults aged ≥65 years who participated in a 24-week randomized, 2x2 factorial, placebo-controlled study comparing WP with an isocaloric placebo-WP and KHCO3 with placebo-KHCO3 designed to evaluate muscle performance. Serum procollagen type 1 intact N-terminal propeptide (PINP), C-terminal telopeptide (CTX), and the uncoupling index (UI, reflecting the relative balance of bone formation and resorption) were measured at baseline and 24 weeks. Between-group differences in 24-week outcomes were estimated using ANCOVA adjusted for baseline value, age, and sex.Results: Among the 117 participants (mean±SD age 73.9±5.8 years), baseline dietary protein intake was 0.85±0.33 g/kg/d, calcium intake 973.0±464.5 mg/d, serum 25-hydroxyvitamin D concentration 37.0±13.9 ng/mL and 24-hour net acid excretion 25.6±20.0 mmol/d. No statistically significant differences between WP and placebo-WP or between KHCO3 and placebo-KHCO3 were observed at 24 weeks for PINP, CTX, or UI. For WP versus placebo-WP, LS mean differences between groups at 24-weeks were -4.4 µg/L for PINP (95% CI -8.8,0.0), -0.1 ng/mL for CTX (-0.1,0.0), and 0.1 for UI (-0.1,0.4). For KHCO3 versus placebo-KHCO3, corresponding differences were -3.2 µg/L (-7.5,1.2), 0.0 ng/mL (−0.1,0.0), and -0.0 (-0.2,0.3).Conclusion: Supplementation with WP or KHCO3 for 24 weeks was not associated with differences in bone turnover markers or the uncoupling index in healthy older adults with generally adequate baseline protein and calcium intakes and vitamin D status.
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessEffect of protein and alkali supplementation on bone turnover markers in healthy older adults
Purpose: To investigate the effects of whey protein (WP; 1.5 g/kg/day) and potassium bicarbonate (KHCO3; 81 mmol/day) supplementation on bone turnover markers in healthy older adults.Methods: We conducted a secondary analysis of healthy adults aged ≥65 years who participated in a 24-week randomized, 2x2 factorial, placebo-controlled study comparing WP with an isocaloric placebo-WP and KHCO3 with placebo-KHCO3 designed to evaluate muscle performance. Serum procollagen type 1 intact N-terminal propeptide (PINP), C-terminal telopeptide (CTX), and the uncoupling index (UI, reflecting the relative balance of bone formation and resorption) were measured at baseline and 24 weeks. Between-group differences in 24-week outcomes were estimated using ANCOVA adjusted for baseline value, age, and sex.Results: Among the 117 participants (mean±SD age 73.9±5.8 years), baseline dietary protein intake was 0.85±0.33 g/kg/d, calcium intake 973.0±464.5 mg/d, serum 25-hydroxyvitamin D concentration 37.0±13.9 ng/mL and 24-hour net acid excretion 25.6±20.0 mmol/d. No statistically significant differences between WP and placebo-WP or between KHCO3 and placebo-KHCO3 were observed at 24 weeks for PINP, CTX, or UI. For WP versus placebo-WP, LS mean differences between groups at 24-weeks were -4.4 µg/L for PINP (95% CI -8.8,0.0), -0.1 ng/mL for CTX (-0.1,0.0), and 0.1 for UI (-0.1,0.4). For KHCO3 versus placebo-KHCO3, corresponding differences were -3.2 µg/L (-7.5,1.2), 0.0 ng/mL (−0.1,0.0), and -0.0 (-0.2,0.3).Conclusion: Supplementation with WP or KHCO3 for 24 weeks was not associated with differences in bone turnover markers or the uncoupling index in healthy older adults with generally adequate baseline protein and calcium intakes and vitamin D status.
- Open Access
- 13 February 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (1) , e10-e17
A Public Health Approach to Antimicrobial Stewardship in Long-term Care Facilities: A Multifaceted Program in Massachusetts
Background: Benchmarking is an effective strategy to improve antibiotic use but remains underutilized in long-term care (LTC). In 2018, the Massachusetts Department of Public Health, in partnership with Tufts Medical Center, launched the Antibiotic Start (AS) Reporting Program, a statewide initiative to monitor and improve antibiotic prescribing in LTC facilities through monthly reporting and feedback, alongside other stewardship interventions. Methods: Long-term care facilities voluntarily submitted monthly AS data through an online platform. AS rates were calculated as AS per 1000 resident-days. Quarterly benchmarking reports and educational activities (introduced in 2022), including LTC office hours webinars, were conducted to support interpretation and engagement. We conducted an interrupted time-series (ITS) analysis to assess changes in beta-lactam and fluoroquinolone prescribing from 2018 to 2024 and a stratified analysis comparing AS rates between facilities with and without honor roll recognition. Results: A total of 217 LTC facilities submitted ≥1 month of AS data. The overall AS rate increased by 7%, from 7.22 to 7.70 per 1000 resident-days. Fluoroquinolone starts decreased by 36%, while beta-lactam starts increased by 26%. Interrupted time series analysis showed a significant rise in beta-lactam use following the October 2022 expansion of benchmarking reports and LTC office hours (P < .001). A subgroup analysis showed higher total and beta-lactam AS rates among honor roll facilities compared with nonrecognized facilities. Conclusions: The Massachusetts AS Reporting Program demonstrates that sustained, data-driven public health–academic collaboration can advance antimicrobial stewardship in LTC. By combining benchmarking, feedback, education, and recognition, public health agencies can support stewardship engagement and promote sustainable improvement in antibiotic use across resource-limited settings.
- 13 February 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (1) , e10-e17
Open AccessA Public Health Approach to Antimicrobial Stewardship in Long-term Care Facilities: A Multifaceted Program in Massachusetts
Background: Benchmarking is an effective strategy to improve antibiotic use but remains underutilized in long-term care (LTC). In 2018, the Massachusetts Department of Public Health, in partnership with Tufts Medical Center, launched the Antibiotic Start (AS) Reporting Program, a statewide initiative to monitor and improve antibiotic prescribing in LTC facilities through monthly reporting and feedback, alongside other stewardship interventions. Methods: Long-term care facilities voluntarily submitted monthly AS data through an online platform. AS rates were calculated as AS per 1000 resident-days. Quarterly benchmarking reports and educational activities (introduced in 2022), including LTC office hours webinars, were conducted to support interpretation and engagement. We conducted an interrupted time-series (ITS) analysis to assess changes in beta-lactam and fluoroquinolone prescribing from 2018 to 2024 and a stratified analysis comparing AS rates between facilities with and without honor roll recognition. Results: A total of 217 LTC facilities submitted ≥1 month of AS data. The overall AS rate increased by 7%, from 7.22 to 7.70 per 1000 resident-days. Fluoroquinolone starts decreased by 36%, while beta-lactam starts increased by 26%. Interrupted time series analysis showed a significant rise in beta-lactam use following the October 2022 expansion of benchmarking reports and LTC office hours (P < .001). A subgroup analysis showed higher total and beta-lactam AS rates among honor roll facilities compared with nonrecognized facilities. Conclusions: The Massachusetts AS Reporting Program demonstrates that sustained, data-driven public health–academic collaboration can advance antimicrobial stewardship in LTC. By combining benchmarking, feedback, education, and recognition, public health agencies can support stewardship engagement and promote sustainable improvement in antibiotic use across resource-limited settings.
- 28 May 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 102 (10) , e209388
Patent Foramen Ovale Closure in Older Patients With Stroke
Whether patent foramen ovale (PFO) closure benefits older patients with PFO and cryptogenic stroke is unknown because randomized controlled trials (RCTs) have predominantly enrolled patients younger than 60 years of age. Our objective was to estimate anticipated effects of PFO closure in older patients to predict the numbers needed to plan an RCT. Effectiveness estimates are derived from major observational studies (Risk of Paradoxical Embolism [RoPE] Study and Oxford Vascular Study, together referred to as the "RoPE-Ox" database) and all 6 major RCTs (Systematic, Collaborative, PFO Closure Evaluation [SCOPE] Consortium). To estimate stroke recurrence risk, observed outcomes were calculated for patients older than 60 years in the age-inclusive observational databases (n = 549). To estimate the reduction in the rate of recurrent stroke associated with PFO closure vs medical therapy based on the RoPE score and the presence of high-risk PFO features, a Cox proportional hazards regression model was developed on the RCT data in the SCOPE database (n = 3,740). These estimates were used to calculate sample sizes required for a future RCT. Five-year risk of stroke recurrence using Kaplan-Meier estimates was 13.7 (95% CI 10.5-17.9) overall, 14.9% (95% CI 10.2-21.6) in those with high-risk PFO features. Predicted relative reduction in the event rate with PFO closure was 12.9% overall, 48.8% in those with a high-risk PFO feature. Using these estimates, enrolling all older patients with cryptogenic stroke and PFO would require much larger samples than those used for prior PFO closure trials, but selectively enrolling patients with high-risk PFO features would require totals of 630 patients for 90% power and 471 patients for 80% power, with an average of 5 years of follow-up. Based on our projections, anticipated effect sizes in older patients with high-risk features make a trial in these subjects feasible. With lengthening life expectancy in almost all regions of the world, the utility of PFO closure in older adults is increasingly important to explore.
- 28 May 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 102 (10) , e209388
Patent Foramen Ovale Closure in Older Patients With Stroke
Whether patent foramen ovale (PFO) closure benefits older patients with PFO and cryptogenic stroke is unknown because randomized controlled trials (RCTs) have predominantly enrolled patients younger than 60 years of age. Our objective was to estimate anticipated effects of PFO closure in older patients to predict the numbers needed to plan an RCT. Effectiveness estimates are derived from major observational studies (Risk of Paradoxical Embolism [RoPE] Study and Oxford Vascular Study, together referred to as the "RoPE-Ox" database) and all 6 major RCTs (Systematic, Collaborative, PFO Closure Evaluation [SCOPE] Consortium). To estimate stroke recurrence risk, observed outcomes were calculated for patients older than 60 years in the age-inclusive observational databases (n = 549). To estimate the reduction in the rate of recurrent stroke associated with PFO closure vs medical therapy based on the RoPE score and the presence of high-risk PFO features, a Cox proportional hazards regression model was developed on the RCT data in the SCOPE database (n = 3,740). These estimates were used to calculate sample sizes required for a future RCT. Five-year risk of stroke recurrence using Kaplan-Meier estimates was 13.7 (95% CI 10.5-17.9) overall, 14.9% (95% CI 10.2-21.6) in those with high-risk PFO features. Predicted relative reduction in the event rate with PFO closure was 12.9% overall, 48.8% in those with a high-risk PFO feature. Using these estimates, enrolling all older patients with cryptogenic stroke and PFO would require much larger samples than those used for prior PFO closure trials, but selectively enrolling patients with high-risk PFO features would require totals of 630 patients for 90% power and 471 patients for 80% power, with an average of 5 years of follow-up. Based on our projections, anticipated effect sizes in older patients with high-risk features make a trial in these subjects feasible. With lengthening life expectancy in almost all regions of the world, the utility of PFO closure in older adults is increasingly important to explore.
- Open Access
- 21 May 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (10) , e033565
Relationship Between Genotype Status and Clinical Outcome in Hypertrophic Cardiomyopathy
Background: The genetic basis of hypertrophic cardiomyopathy (HCM) is complex, and the relationship between genotype status and clinical outcome is incompletely resolved. Methods and Results: We assessed a large international HCM cohort to define in contemporary terms natural history and clinical consequences of genotype. Consecutive patients (n=1468) with established HCM diagnosis underwent genetic testing. Patients with pathogenic (or likely pathogenic) variants were considered genotype positive (G+; n=312; 21%); those without definite disease‐causing mutations (n=651; 44%) or variants of uncertain significance (n=505; 35%) were considered genotype negative (G−). Patients were followed up for a median of 7.8 years (interquartile range, 3.5–13.4 years); HCM end points were examined by cumulative event incidence. Over follow‐up, 135 (9%) patients died, 33 from a variety of HCM‐related causes. After adjusting for age, all‐cause and HCM‐related mortality did not differ between G− versus G+ patients (hazard ratio [HR], 0.78 [95% CI, 0.46–1.31]; P =0.37; HR, 0.93 [95% CI, 0.38–2.30]; P =0.87, respectively). Adverse event rates, including heart failure progression to class III/IV, heart transplant, or heart failure death, did not differ (G− versus G+) when adjusted for age (HR, 1.20 [95% CI, 0.63–2.26]; P =0.58), nor was genotype independently associated with sudden death event risk (HR, 1.39 [95% CI, 0.88–2.21]; P =0.16). In multivariable analysis, age was the only independent predictor of all‐cause and HCM‐related mortality, heart failure progression, and sudden death events. Conclusions: In this large consecutive cohort of patients with HCM, genotype (G+ or G−) was not a predictor of clinical course, including all‐cause and HCM‐related mortality and risk for heart failure progression or sudden death. G+ status should not be used to dictate clinical management or predict outcome in HCM.
- 21 May 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (10) , e033565
Open AccessRelationship Between Genotype Status and Clinical Outcome in Hypertrophic Cardiomyopathy
Background: The genetic basis of hypertrophic cardiomyopathy (HCM) is complex, and the relationship between genotype status and clinical outcome is incompletely resolved. Methods and Results: We assessed a large international HCM cohort to define in contemporary terms natural history and clinical consequences of genotype. Consecutive patients (n=1468) with established HCM diagnosis underwent genetic testing. Patients with pathogenic (or likely pathogenic) variants were considered genotype positive (G+; n=312; 21%); those without definite disease‐causing mutations (n=651; 44%) or variants of uncertain significance (n=505; 35%) were considered genotype negative (G−). Patients were followed up for a median of 7.8 years (interquartile range, 3.5–13.4 years); HCM end points were examined by cumulative event incidence. Over follow‐up, 135 (9%) patients died, 33 from a variety of HCM‐related causes. After adjusting for age, all‐cause and HCM‐related mortality did not differ between G− versus G+ patients (hazard ratio [HR], 0.78 [95% CI, 0.46–1.31]; P =0.37; HR, 0.93 [95% CI, 0.38–2.30]; P =0.87, respectively). Adverse event rates, including heart failure progression to class III/IV, heart transplant, or heart failure death, did not differ (G− versus G+) when adjusted for age (HR, 1.20 [95% CI, 0.63–2.26]; P =0.58), nor was genotype independently associated with sudden death event risk (HR, 1.39 [95% CI, 0.88–2.21]; P =0.16). In multivariable analysis, age was the only independent predictor of all‐cause and HCM‐related mortality, heart failure progression, and sudden death events. Conclusions: In this large consecutive cohort of patients with HCM, genotype (G+ or G−) was not a predictor of clinical course, including all‐cause and HCM‐related mortality and risk for heart failure progression or sudden death. G+ status should not be used to dictate clinical management or predict outcome in HCM.
- 1 January 2022
- Published by Elsevier in The American Journal of Cardiology
- Vol. 163, 91-97
Outcomes Over Follow-up ≥10 Years After Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy
- 1 January 2022
- Published by Elsevier in The American Journal of Cardiology
- Vol. 163, 91-97
Outcomes Over Follow-up ≥10 Years After Surgical Myectomy for Symptomatic Obstructive Hypertrophic Cardiomyopathy
- Open Access
- 1 September 2020
- Published by Elsevier in Journal of the American Society of Echocardiography
- Vol. 33 (12) , 1528-1531
Paradoxical Low-Flow Low-Gradient Aortic Stenosis: Effect of Low Transvalvular Flow Conditions on Indexed Stroke Volume after Transcatheter Aortic Valve Replacement
- 1 September 2020
- Published by Elsevier in Journal of the American Society of Echocardiography
- Vol. 33 (12) , 1528-1531
Open AccessParadoxical Low-Flow Low-Gradient Aortic Stenosis: Effect of Low Transvalvular Flow Conditions on Indexed Stroke Volume after Transcatheter Aortic Valve Replacement